Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05674786 · ClinicalTrials.gov registry record · NA

Vestibular Implantation to Treat Adult-Onset Bilateral Vestibular Hypofunction

A NA study of Vestibular Diseases and Sensation Disorders, sponsored by Johns Hopkins University.

Recruiting
Registry status
NA
Development phase
8
Enrollment target
1
Study location

NCT05674786: Recruiting NA study of Vestibular Diseases and Sensation Disorders, sponsored by Johns Hopkins University.

NCT05674786 is a NA study of Vestibular Diseases and Sensation Disorders that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 8 participants, below the 13,370-participant average among 6 other Vestibular Diseases trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05674786, a NA study of Vestibular Diseases and Sensation Disorders, is actively recruiting participants, sponsored by Johns Hopkins University.

RECRUITING
Registry status
NA
Development phase
8 participants
Enrollment target
1
Study location

Study Summary

Although cochlear implants can restore hearing to individuals who have lost cochlear hair cell function, there is no widely available, adequately effective treatment for individuals suffering chronic imbalance, postural instability and unsteady vision due to bilateral vestibular hypofunction. Prior research focused on ototoxic cases has demonstrated that electrical stimulation of the vestibular nerve via a chronically implanted multichannel vestibular implant can partially restore vestibular reflexes that normally maintain steady posture and vision; improve performance on objective measures of postural stability and gait; and improve patient-reported disability and health-related quality of life. This single-arm open-label study extends that research to evaluate outcomes for up to 8 individuals with non-ototoxic bilateral vestibular hypofunction, yielding a total of fifteen adults (age 22-90 years at time of enrollment) divided as equally as possible between ototoxic and non-ototoxic cases.

Primary Outcome

DGI comprises 8 gait tasks scored by an examiner: walking on a level surface, changing gait speed, walking during horizontal head turns, walking during vertical head turns, pivoting, stepping over an obstacle, stepping around obstacles, and waling up and down stairs. Each task is scored (0-3 points, 3 is best). Raw DGI score is the sum of the eight subtest scores and ranges from 0 to 24, with higher scores meaning better outcome and minimally important difference 3.2 points.

Conditions Studied

Vestibular Diseases Sensation Disorders Gentamicin Ototoxicity Labyrinth Diseases Bilateral Vestibular Hypofunction Other Disorders of Vestibular Function, Bilateral Bilateral Vestibular Deficiency (BVD) Bilateral Vestibulopathy Aminoglycoside Ototoxicity

Interventions

  • DEVICE Labyrinth Devices MVI™ Multichannel Vestibular Implant System

Study Locations (1)

Maryland

  • Johns Hopkins School of Medicine - Baltimore

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2023-02-28
Est. Completion 2027-03-31
Phase NA
Johns Hopkins University

1,448 total trials

What NCT05674786 shows while recruiting

NCT05674786 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 13,370-participant average among 6 other Vestibular Diseases trials with a reported enrollment target (100% lower).

The record links to 9 conditions, with Vestibular Diseases appearing as the primary indexed condition, and to 1 intervention - of which Labyrinth Devices MVI™ Multichannel Vestibular Implant System is the first listed.

NCT05674786 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT05674786 about?

NCT05674786 is a clinical study titled "Vestibular Implantation to Treat Adult-Onset Bilateral Vestibular Hypofunction". Although cochlear implants can restore hearing to individuals who have lost cochlear hair cell function, there is no widely available, adequately effective treatment for individuals suffering chronic imbalance, postural instability and unsteady vision due to bilateral vestibular hypofunction. Prior ...

What is the current status of trial NCT05674786?

This trial is currently recruiting. It is a NA study. The enrollment target is 8 participants. The study started on 2023-02-28. Estimated completion is 2027-03-31.

What conditions does trial NCT05674786 study?

This clinical trial studies the following conditions: Vestibular Diseases, Sensation Disorders, Gentamicin Ototoxicity, Labyrinth Diseases, Bilateral Vestibular Hypofunction.

What interventions are being tested in trial NCT05674786?

The interventions under investigation include: Labyrinth Devices MVI™ Multichannel Vestibular Implant System (DEVICE).

Who is sponsoring clinical trial NCT05674786?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05674786 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Vestibular Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05674786

Source: ClinicalTrials.gov NCT05674786, the US trial registry maintained by the National Library of Medicine. NCT05674786 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.